FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.
FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.
复制标题
DOI：
10.3892/ijo.2015.2817
复制
发表时间：
2015-03
影响因子：
5.2
通讯作者：
Suzuki H
中科院分区：
文献类型：
--
作者：
Okabe N;Ezaki J;Yamaura T;Muto S;Osugi J;Tamura H;Imai J;Ito E;Yanagisawa Y;Honma R;Gotoh M;Watanabe S;Waguri S;Suzuki H
非小细胞肺癌（NSCLC），特别是肺腺癌的个体化治疗，最近已显着提高了各种分子靶点的发现。然而，肺鳞状细胞癌（SCC）的情况并非如此。在本研究中，我们确定了家庭与序列相似性83，成员B（FAM 83 B）作为一个候选标记SCC通过全面的基因表达分析，并检查其与各种临床病理因素的相关性。本研究的受试者包括2005年至2011年在福岛医科大学医院（福岛，日本）接受完全切除术的215例NSCLC患者。其中包括102例腺癌患者和113例SCC患者。首先通过基因表达分析和蛋白质印迹法检测部分样本中的FAM 83 B表达，然后通过免疫组织化学（IHC）评估所有临床标本。统计分析IHC定量值与临床病理因素的关系。结果表明，FAM 83 B mRNA在鳞癌中的表达明显高于正常肺组织和腺癌（P<0.0001）。免疫印迹分析也证实了这一趋势。FAM 83 B阳性面积>10%的标本判定为“阳性”; 94.3%（107/113）的SCC和14.7%（15/102）的腺癌为阳性。根据表达将患者分为两个亚组（54例高表达和53例低表达患者）;高表达组与更好的无病生存率（DFS）相关（P=0.042，对数秩检验）。FAM 83 B可能是一个可靠的诊断和预后SCC的生物标志物。需要对肺癌中FAM 83 B功能进行详细分析，以了解其表达如何与SCC中的更好预后相关。
Personalized therapy for non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, has recently been significantly improved by the discovery of various molecular targets. However, this has not been the case for lung squamous cell carcinoma (SCC). In the present study, we identified the family with sequence similarity 83, member B (FAM83B) as a candidate marker for SCC through a comprehensive gene expression analysis and examined its correlations with various clinicopathological factors. The subjects of this study consisted of 215 patients with NSCLC who underwent complete resection from 2005 to 2011 at the Fukushima Medical University Hospital (Fukushima, Japan). They included 102 patients with adenocarcinoma and 113 with SCC. FAM83B expression was first examined in some of the samples by gene expression analysis and western blotting, and then all clinical specimens were evaluated by immunohistochemistry (IHC). The relationship between the quantitative values for IHC and clinicopathological factors was statistically analyzed. The results showed that FAM83B mRNA expression was significantly higher in SCC than in normal lung or adenocarcinoma (P<0.0001). Immunoblot analysis also confirmed this trend. Specimens containing >10% positive area for FAM83B were judged as ‘positive’; 94.3% (107/113) of SCC and 14.7% (15/102) of adenocarcinoma were positive. Patients were divided into two subgroups according to expression (54 high-expression and 53 low-expression patients); the high-expression group was associated with a better disease-free survival (DFS) rate (P=0.042, log-rank test). In conclusion, FAM83B may be a reliable diagnostic and prognostic biomarker for SCC. Detailed analyses of FAM83B function in lung cancer are required to understand how its expression is associated with better prognosis in SCC.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
--
作者：
Cipriano R;Miskimen KL;Bryson BL;Foy CR;Bartel CA;Jackson MW
通讯作者：
Jackson MW
三席拉克（Triple Silac）确定Wnt途径中的刺激特定相互作用。
影响因子：
4.4
作者：
Hilger, Maximiliane;Mann, Matthias
通讯作者：
Mann, Matthias
影响因子：
45.3
作者：
Scagliotti, Giorgio Vittorio;Parikh, Purvish;Gandara, David
通讯作者：
Gandara, David
影响因子：
15.9
作者：
Cipriano, Rocky;Graham, James;Jackson, Mark W.
通讯作者：
Jackson, Mark W.